Search results
DOACs versus LMWH in Prevention of VTE Recurrence in Cancer Patients
Added:
10 months ago
Systematic Review
Added:
1 year ago
EHRA 24 - Investigator, Dr Boris Schmidt (Cardioangiologisches Centrum Bethanien, DE) is interviewed on ablation strategies for repeat procedures in patients with recurrent atrial fibrillation (AF).The ASTRO trial is a multi-centre prospective randomized study that enrolled 256 patients with drug-refractory AF despite previous AF ablation. The trial showed no statistically significant differences…
View more
Added:
3 weeks ago
In this episode of Arrhythmia Academy's Journal Club, Dr David Duncker (Hannover Heart Rhythm Center, DE) is joined by Dr Marat Fudim (Duke University, US) to examine the critical early-risk period following heart failure diagnosis and the emerging role of wearable cardioverter defibrillators in sudden cardiac death prevention.The discussion centres on findings from the SCD-PROTECT study, a 19…
View more
Added:
2 days ago
Source:
Arrhythmia Academy
Artificial intelligence applied to electrocardiograms (ECG-AI) may offer a scalable way to identify individuals at high risk of developing heart failure (HF), potentially improving on current clinical risk estimators, according to a new pooled cohort analysis from the HeartShare/Accelerating Medicines Partnership (AMP) Heart Failure program.¹The study aimed to assess whether ECG-AI models…
View more
Added:
11 months ago
ACC 2025 - EVOLUT Low-Risk findings show the Medtronic TAVR system is a safe and effective treatment for aortic stenosis vs surgical valves at five years.Dr Michael Reardon (Houston Methodist, Texas, US) joins us onsite at ACC to discuss the EVOLUT Low Risk trial (NCT02701283; Medtronic Cardiovascular), investigating the safety and effectiveness of the Medtronic TAVR system compared to surgical…
View more
Added:
3 months ago
AHA Scientific Sessions 2025 – Dr Chao Jiang and Dr Zhao Zixu (Beijing Anzhen Hospital, CN) discuss the findings from the DARE-AF (NCT06433479) randomized clinical trial, investigating whether dapagliflozin reduces atrial fibrillation burden following catheter ablation in patients without diabetes or heart failure.This single-center, open-label trial enrolled 200 patients with persistent atrial…
View more
Added:
5 months ago
Filmed onsite at EASD 2025, this on-demand series features key insights from Prof Dirk Müller-Wieland and Dr Rahul Aggarwal to interpret the latest data on eicosapentaenoic acid(EPA), including the latest sub-analysis of the REDUCE-IT trial, whichanalysed the effectiveness of icosapent ethyl (IPE) on CV risk by triglyceride-glucose (TyG) index - an indicator of insulin resistance and risk of type…
View more
GLP-1 RAs in T2D and Established or High-risk ASCVD
Added:
10 months ago
Expert Opinion
Added:
11 months ago
ACC 2025 - Individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause.Prof Christina Magnussen (University Heart and Vascular Centre Hamburg, Hamberg, DE) joins us onsite at ACC to discuss modifiable cardiovascular risk factors collected by the Global…
View more
Risk Prediction of CVD in the Asia-Pacific Region
Added:
1 year ago
Original Research